Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease
Top Cited Papers
Open Access
- 6 November 2014
- journal article
- Published by American Society of Hematology in Blood
- Vol. 124 (19) , 3016-3019
Abstract
Key Points: PIK3CA and NRAS mutations are recurrent in BRAFV600E wild-type ECD patients. 57.5% (46/80) of ECD patients have a BRAFV600E mutation, and an additional 10.9% and 3.7% have PIK3CA and NRAS mutations, respectively.Keywords
This publication has 19 references indexed in Scilit:
- Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutationBlood, 2013
- BRAF Mutations in Erdheim-Chester DiseaseJournal of Clinical Oncology, 2013
- Detection of BRAF p.V600E Mutations in MelanomasThe Journal of Molecular Diagnostics, 2013
- High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytosesBlood, 2012
- Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaNew England Journal of Medicine, 2012
- PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced CancersPLOS ONE, 2011
- CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patientsBlood, 2011
- Detection of KRAS and BRAF Mutations in Colorectal CarcinomaThe Journal of Molecular Diagnostics, 2011
- Recurrent BRAF mutations in Langerhans cell histiocytosisBlood, 2010
- Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for ResistanceCancer Research, 2008